SANGAMO THERAPEUTICS INC Form 4 Filings

Sangamo Therapeutics’ Principal Accounting Officer, Nikunj Jain, reported a routine tax-withholding transaction tied to restricted stock unit (RSU) vesting. On May 25, 2026, 1,919 shares of common stock were surrendered to the company at $0.1743 per share to cover mandatory taxes.

This disposition was required under the company’s 2018 Equity Incentive Plan and was not an open-market trade. After this withholding, Jain directly holds 235,292 shares. The RSU grant that partially vested on this date delivered 2,742 shares, with 32,633 additional shares scheduled to vest in seven equal quarterly installments, subject to continued service.

Sangamo Therapeutics senior vice president and chief development officer Nathalie Dubois-Stringfellow reported a tax-related share disposition. She surrendered 4,036 shares of common stock at a value of $0.1743 per share to cover mandatory tax withholding on a restricted stock unit (RSU) vesting that occurred on May 25, 2026.

This transaction is classified as a required tax-withholding disposition to the company, not a discretionary open-market trade. After the withholding, she directly holds 328,733 shares of common stock. The vesting relates to a February 25, 2025 RSU grant under the company’s 2018 equity incentive plan.

Sangamo Therapeutics SVP Scott B. Willoughby reported a routine tax-withholding share disposition tied to restricted stock vesting. On May 25, 2026, 4,036 shares of common stock were surrendered to the company at $0.1743 per share solely to satisfy mandatory tax withholding on vested RSUs, not as an open-market trade. After this non-discretionary transaction, he directly holds 647,370 shares. A footnote notes that 7,214 shares vested from a February 25, 2025 RSU grant on the same date, with 78,750 additional RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service.

Sangamo Therapeutics CEO Sandy Macrae reported a tax-withholding disposition of 12,613 shares of Common Stock. These shares came from a restricted stock unit (RSU) grant vesting on May 25, 2026 and were surrendered to the company solely to cover mandatory taxes at $0.1743 per share.

The filing notes this is treated as a disposition to the issuer for reporting purposes but is not a discretionary open-market trade. After this transaction, Macrae holds 1,895,043 shares directly. The vesting event included 22,543 shares from a February 25, 2025 RSU grant, with 246,094 additional RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service.

Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, sold common stock in an open-market transaction. On April 22, 2026, he sold 69,827 shares of Sangamo Therapeutics common stock at a weighted-average price of $0.2534 per share, with individual trades ranging from $0.2533 to $0.2568. After this sale, Davis directly holds 115,284 shares of the company’s common stock.

Sangamo Therapeutics SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported an open-market sale of Common Stock. She sold 345,942 shares on April 21, 2026 at a weighted-average price of $0.2578 per share in multiple trades ranging from $0.2533 to $0.2634.

Following this transaction, she directly holds 332,769 shares of Sangamo Therapeutics Common Stock. The filing does not report any derivative security exercises, indicating this was a straightforward share sale rather than an option-related transaction.

Sangamo Therapeutics senior vice president and chief development officer Nathalie Dubois-Stringfellow received a grant of stock options covering 800,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.

One quarter of the options will vest on the first anniversary of the grant date, with the remaining options vesting in 24 equal monthly installments, contingent on her continued service under the company’s 2018 equity incentive plan.

Sangamo Therapeutics Principal Accounting Officer Nikunj Jain received a grant of stock options as equity compensation. The award covers 225,000 options to buy common stock at an exercise price of $0.2601 per share, expiring on March 31, 2036.

One quarter of the options vest on the first anniversary of the grant date, and the remaining options vest in 24 equal monthly installments, subject to Mr. Jain’s continuous service and the terms of the company’s 2018 equity incentive plan. No open‑market share purchases or sales were reported in this filing.

Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a new stock option grant. The award covers 225,000 stock options for common shares at an exercise price of $0.2601 per share, expiring on March 31, 2036.

One-quarter of the options will vest on the first anniversary of the grant, with the remaining options vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan. After this grant, he holds 225,000 derivative securities directly.

Sangamo Therapeutics reported that its President, CEO and Director, Sandy Macrae, received a grant of stock options covering 2,500,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.

According to the vesting terms, one-quarter of the option shares will vest and become exercisable on the first anniversary of the grant date, with the remaining shares vesting in 24 equal monthly installments after that, subject to Dr. Macrae’s continuous service and the provisions of the company’s 2018 Equity Incentive Plan.

Sangamo Therapeutics reported that SVP and Chief Legal Officer Scott B. Willoughby received a grant of stock options covering 800,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.

These options were granted as compensation and do not represent an open-market purchase or sale. One quarter of the options will vest after one year from the grant date, with the remaining shares vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan.

Sangamo Therapeutics senior executive reports share dispositions tied to RSU tax withholding. SVP and Chief Development Officer Nathalie Dubois-Stringfellow surrendered 2,063 common shares at $0.4725 per share on February 24, 2026 and 12,354 shares at $0.47 per share on February 25, 2026.

Both transactions were required to cover taxes on restricted stock units that had just vested under the company’s 2018 Equity Incentive Plan and were deemed dispositions to the company, not discretionary open‑market trades. After these transactions, she directly owns 678,711 common shares.

Sangamo Therapeutics President and CEO Sandy Macrae reported two required tax-withholding dispositions of common stock tied to vested restricted stock units. On February 24, 2026, 5,291 shares were surrendered at $0.4725 per share, and on February 25, 2026, 33,637 shares were surrendered at $0.47 per share. The footnotes state these transactions were made solely to cover mandatory tax obligations under the company’s equity incentive plan and were not discretionary open-market trades. After these transactions, Macrae directly held 1,907,656 shares of common stock.

Sangamo Therapeutics SVP and Chief Legal Officer Scott B. Willoughby reported mandatory tax-withholding share dispositions tied to restricted stock unit (RSU) vesting. On February 24, 2026, 1,650 common shares were surrendered at $0.4725 per share, and on February 25, 2026, 12,354 common shares were surrendered at $0.47 per share.

In both cases, the shares were delivered back to the company solely to cover tax liabilities upon RSU vesting under Sangamo’s 2018 Equity Incentive Plan and were not discretionary open-market trades. After these transactions, Willoughby directly owned 651,406 shares of Sangamo common stock.

Sangamo Therapeutics principal accounting officer Nikunj Jain reported two share dispositions tied to restricted stock unit (RSU) vesting and tax withholding. On February 24, 2026, 666 shares of common stock were surrendered at $0.4725 per share to satisfy mandatory tax obligations on vested RSUs.

On February 25, 2026, an additional 5,119 shares were surrendered at $0.47 per share for the same tax-withholding purpose under the company’s 2018 Equity Incentive Plan. These transactions are reported as dispositions to the company and are explicitly described as non-discretionary, not open-market trades.

Sangamo Therapeutics Head of Research & Technology Gregory D. Davis reported mandatory tax-related share dispositions tied to vesting restricted stock units. On February 24, 2026, 832 shares of common stock were surrendered at $0.4725 per share for required tax withholding. On February 25, 2026, an additional 5,119 shares were surrendered at $0.47 per share, also solely to cover tax obligations under the company’s 2018 equity incentive plan. These transactions are recorded as dispositions to the company for reporting purposes and are not discretionary open‑market trades. Following the later transaction, Davis directly owned 185,111 common shares.

Sangamo Therapeutics’ Principal Accounting Officer, Nikunj Jain, reported an automatic share withholding tied to restricted stock units. On January 22, 2026, 7,721 shares of common stock underlying a vested RSU tranche were surrendered back to Sangamo at $0.3985 per share to cover mandatory tax withholding under the company’s 2018 Equity Incentive Plan. This is treated as a disposition for reporting purposes but is not a discretionary open-market trade.

After this tax withholding event, Jain beneficially owned 242,996 shares, including RSUs from grants dated February 24, 2023, January 22, 2024, and February 25, 2025 that vest over time, as well as 5,000 shares acquired under the 2020 Employee Stock Purchase Plan.

Sangamo Therapeutics’ principal financial officer, Prathyusha Duraibabu, reported an automatic share withholding tied to restricted stock vesting. On January 22, 2026, 36,676 shares of common stock were surrendered to the company at $0.3985 per share to cover mandatory tax withholding on a vested restricted stock unit (RSU) grant. This is treated as a disposition to the issuer for reporting purposes but was not a discretionary sale in the open market.

After this tax withholding event, the officer beneficially owned 660,042 shares of common stock, including shares underlying multiple RSU grants that vest over time, subject to continued service under the company’s 2018 Equity Incentive Plan.

Sangamo Therapeutics executive Scott B. Willoughby, SVP, Chief Legal Officer and Secretary, reported a routine share disposition tied to equity compensation. On January 22, 2026, 36,676 shares of common stock were surrendered to Sangamo solely for mandatory tax withholding on a restricted stock unit (RSU) vesting, using the company’s closing stock price of $0.3985 per share. This is treated as a disposition to the issuer for reporting purposes but was not a discretionary trade in the open market.

After this transaction, Willoughby beneficially owned 665,410 shares of common stock. This amount includes 52,387 shares from the January 22, 2026 vesting of a January 22, 2024 RSU grant, 4,008 RSU shares scheduled to vest quarterly through February 24, 2026, and 120,000 RSU shares from a February 25, 2025 grant that will vest beginning February 25, 2026, subject to continued service and potential acceleration under the company’s 2018 Equity Incentive Plan.

Sangamo Therapeutics president and CEO Sandy Macrae reported a Form 4 transaction involving company common stock. On January 22, 2026, 102,950 shares were automatically surrendered at a price of $0.3985 per share to cover mandatory tax withholding tied to the vesting of restricted stock units under Sangamo’s 2018 Equity Incentive Plan. This is treated as a disposition to the company for reporting purposes but was not a discretionary open-market trade. After this tax-withholding event, Macrae beneficially owned 1,946,584 shares of Sangamo common stock, including multiple RSU grants that continue to vest over time, subject to ongoing service conditions.

Sangamo Therapeutics reported an insider equity transaction by Davis Gregory D, its Head of Research & Technology. On January 22, 2026, a portion of his restricted stock units vested and 7,721 shares of common stock were surrendered solely to cover mandatory tax withholding at a price of $0.3985 per share under the company’s 2018 Equity Incentive Plan.

After this tax withholding event, he beneficially owns 191,062 shares of common stock, including vested and unvested RSUs and 5,000 shares previously acquired through the 2020 Employee Stock Purchase Plan. The filing notes this is a required tax withholding transaction and not a discretionary open-market sale.

Sangamo Therapeutics, Inc. reported an insider equity transaction by SVP and Chief Development Officer Nathalie Dubois-Stringfellow. On January 22, 2026, 36,676 shares of common stock were surrendered at $0.3985 per share to cover mandatory tax withholding on a vesting restricted stock unit (RSU) grant, under the company’s 2018 Equity Incentive Plan. This is treated as a disposition to the company for reporting purposes but was not a discretionary open-market trade.

Following this tax withholding event, Dubois-Stringfellow beneficially owned 693,128 shares of Sangamo common stock. This total includes previously vested RSUs, unvested RSUs that will vest over time if service continues, and shares acquired under the company’s 2020 Employee Stock Purchase Plan.

Sangamo Therapeutics officer and Principal Accounting Officer reported an automatic share disposition related to restricted stock units. On November 24, 2025, 578 shares of common stock were surrendered to the company solely to cover mandatory tax withholding on a vesting RSU grant, using the issuer's closing stock price of $0.4166 per share. This is treated as a disposition to the issuer for reporting purposes but is not a discretionary open-market trade.

After this transaction, the reporting person beneficially owned 245,717 shares, including shares from multiple RSU grants that vest over time through February 24, 2026 and beyond, subject to continued service and the terms of the company’s 2018 Equity Incentive Plan.

Sangamo Therapeutics (SGMO) filed a Form 4 for its SVP, Chief Legal Officer and Secretary, reporting an automatic share withholding tied to restricted stock units (RSUs). On November 24, 2025, 2,035 shares of common stock were surrendered to the company solely to cover mandatory tax withholding, using a closing stock price of $0.4166 per share. After this tax transaction, the reporting person beneficially owned 702,086 shares.

The filing explains that these holdings include multiple RSU grants with scheduled vesting through early 2027, all conditioned on continued service. This transaction is characterized as required tax withholding and not a discretionary trade in the open market.

Sangamo Therapeutics (SGMO) reported an insider equity transaction involving its President, CEO and Director. On November 24, 2025, the executive had 7,488 shares of common stock withheld and treated as disposed of at $0.4166 per share to cover mandatory tax obligations tied to a restricted stock unit (RSU) vesting event under the company’s 2018 Equity Incentive Plan. This was not an open-market or discretionary sale.

Following this tax withholding, the executive beneficially owned 2,049,534 shares, including multiple RSU grants that vest over time, such as shares from a February 24, 2023 grant, a January 22, 2024 grant vesting in equal quarterly installments through January 22, 2026, and a February 25, 2025 grant with vesting starting February 25, 2026. All RSU vesting remains contingent on continued service and potential acceleration provisions under the plan.

Sangamo Therapeutics, Inc. executive share transaction disclosure

Sangamo Therapeutics' principal financial officer reported an automatic share transaction related to restricted stock units. On November 24, 2025, 2,544 shares of common stock were surrendered to the company at $0.4166 per share to cover mandatory tax withholding when a portion of a restricted stock unit (RSU) award vested. This is recorded as a disposition to the issuer for reporting purposes but was not a discretionary open-market trade.

After this tax withholding event, the officer beneficially owned 696,718 shares of common stock, including multiple RSU grants that continue to vest over time, subject to continued service and potential acceleration under the company’s 2018 Equity Incentive Plan.

Sangamo Therapeutics (SGMO) reported a routine insider equity transaction by its SVP-Chief Development Officer on a Form 4. On November 24, 2025, the officer surrendered 2,544 shares of common stock at $0.4166 per share solely to cover mandatory tax withholding on a vesting restricted stock unit (RSU) grant under the company’s 2018 Equity Incentive Plan. This withholding is treated as a disposition to the company for reporting purposes but is not a discretionary open-market trade.

Following this tax withholding event, the officer beneficially owned 719,804 shares of common stock. The explanation notes ongoing RSU vesting schedules from grants made in February 2023, January 2024, and February 2025, all subject to continued service and potential acceleration as provided in the equity plan.

Sangamo Therapeutics (SGMO) reported an insider equity transaction by its Head of Research & Technology on Form 4. On November 24, 2025, 723 shares of common stock were surrendered to the company to cover mandatory tax withholding on a restricted stock unit (RSU) vesting, using the closing stock price of $0.4166 per share. This is treated as a disposition to the issuer for reporting purposes but was not a discretionary market trade.

After this tax withholding, the reporting person beneficially owned 193,791 shares, including shares from several RSU grants that vested or are scheduled to vest under Sangamo’s 2018 Equity Incentive Plan, subject to continuous service and potential acceleration under the plan.

Sangamo Therapeutics (SGMO) insider filing: The SVP–Chief Development Officer reported a routine tax-withholding transaction tied to RSU vesting. On 10/22/2025, 43,741 shares were surrendered at $0.66 under Code F to cover mandatory taxes from an RSU vesting event. Following the transaction, beneficial ownership stands at 722,348 shares (direct).

The filing notes RSU activity and schedules: 45,321 shares vested on 10/22/2025 from a 1/22/2024 grant; 89,063 shares from that grant are scheduled to vest in equal quarterly installments through 1/22/2026. It also lists 10,020 shares from a 2/24/2023 grant vesting quarterly through 2/24/2026 and 120,000 shares from a 2/25/2025 grant vesting one-fourth on 2/25/2026 with the remainder in eight equal quarterly installments thereafter, each subject to continuous service.

Sangamo Therapeutics (SGMO) reported an insider transaction on Form 4. The company’s SVP, Chief Legal Officer and Secretary executed a tax-withholding disposition tied to RSU vesting on 10/22/2025. 44,122 shares of common stock were withheld (code F) at $0.66 per share using the issuer’s closing price. Following the transaction, the reporting person beneficially owns 704,121 shares, held directly.

The filing notes these shares were surrendered solely to cover taxes upon vesting under the Amended and Restated 2018 Equity Incentive Plan and do not reflect an open-market sale. It also outlines remaining RSU vesting schedules, including portions from grants dated 1/22/2024, 2/24/2023, and 2/25/2025, subject to continuous service and plan terms.

Sangamo Therapeutics (SGMO) insider filing: the President, CEO and Director reported an automatic share withholding tied to RSU vesting. On October 22, 2025, 126,950 shares were withheld for mandatory taxes at a price of $0.66 per share, following the vesting of a portion of a restricted stock unit grant. After these transactions, the reporting person beneficially owned 2,057,022 shares, held directly.

The filing notes RSU schedules: 123,050 shares resulted from the October 22, 2025 vesting installment of a January 22, 2024 grant, with the remaining 250,000 shares vesting in equal quarterly installments through January 22, 2026. It also includes 29,494 shares from a February 24, 2023 grant vesting in equal quarterly installments through February 24, 2026, and 375,000 shares from a February 25, 2025 grant vesting one-fourth on February 25, 2026, with the balance in eight successive equal quarterly installments thereafter. All vesting is subject to continuous service and the plan’s terms.

Sangamo Therapeutics (SGMO) officer files Form 4 disclosing a tax-withholding transaction tied to RSU vesting. On 10/22/2025, the Principal Financial Officer surrendered 45,225 shares at $0.66 per share under transaction code F, which reflects shares withheld for taxes, not an open‑market sale.

Following the transaction, the officer beneficially owned 699,262 shares. The filing notes RSU activity and schedules: 43,837 shares vested on 10/22/2025 from a 1/22/2024 grant, with 89,063 shares scheduled to vest in equal quarterly installments through 1/22/2026; 10,020 shares from a 2/24/2023 grant vest in equal quarterly installments through 2/24/2026; and 120,000 shares from a 2/25/2025 grant vest 1/4 on 2/25/2026 and the balance in eight successive equal quarterly installments thereafter, subject to continuous service and potential acceleration under the company’s 2018 Equity Incentive Plan.

Sangamo Therapeutics (SGMO): A company officer reported an administrative share withholding tied to RSU vesting. On October 22, 2025, 6,708 shares were surrendered to the issuer solely for mandatory tax withholding at $0.66 per share. This was not an open‑market trade.

Following the transaction, the officer reports 246,295 shares beneficially owned. The filing notes ongoing RSU schedules, including shares from the January 22, 2024, February 24, 2023, and February 25, 2025 grants with vesting through 2026, conditioned on continuous service.

Sangamo Therapeutics (SGMO) reported an insider tax-withholding transaction tied to RSU vesting. On 10/22/2025, the Head of Research & Technology surrendered 6,708 shares at $0.66 per share for mandatory tax withholding, a disposition to the issuer that is not an open‑market trade.

Following the transaction, the insider beneficially owned 194,514 shares. The RSU details note 12,042 shares vested on 10/22/2025, with remaining tranches of 18,750, 4,043, and 49,726 shares scheduled to vest per grant terms, subject to continuous service and potential acceleration under the 2018 EIP.